Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Oct 7;3(10):e223503.
doi: 10.1001/jamahealthforum.2022.3503.

Financial Incentives to Facilities and Clinicians Treating Patients With End-stage Kidney Disease and Use of Home Dialysis: A Randomized Clinical Trial

Yunan Ji  1 , Liran Einav  2   3 , Neale Mahoney  2   3   4 , Amy Finkelstein  3   4   5
Affiliations
Randomized Controlled Trial

Financial Incentives to Facilities and Clinicians Treating Patients With End-stage Kidney Disease and Use of Home Dialysis: A Randomized Clinical Trial

Yunan Ji et al. JAMA Health Forum. .

Abstract

Importance: Home dialysis rates for end-stage kidney disease (ESKD) treatment are substantially lower in the US than in other high-income countries, yet there is limited knowledge on how to increase these rates.

Objective: To report results from the first year of a nationwide randomized clinical trial that provides financial incentives to ESKD facilities and managing clinicians to increase home dialysis rates.

Design, setting, and participants: Results were analyzed from the first year of the End-Stage Renal Disease Treatment Choice (ETC) model, a multiyear, mandatory-participation randomized clinical trial designed and implemented by the US Center for Medicare & Medicaid Innovation. Data were reported on Medicare patients with ESKD 66 years or older who initiated treatment with dialysis in 2021, with data collection through December 31, 2021; the study included all eligible ESKD facilities and managing clinicians. Eligible hospital referral regions (HRRs) were randomly assigned to the ETC (91 HRRs) or a control group (211 HRRs).

Interventions: The ESKD facilities and managing clinicians received financial incentives for home dialysis use.

Main outcomes and measures: The primary outcome was the percentage of patients with ESKD who received any home dialysis during the first 90 days of treatment. Secondary outcomes included other measures of home dialysis and patient volume and characteristics.

Results: Among the 302 HRRs eligible for randomization, 18 621 eligible patients initiated dialysis treatment during the study period (mean [SD] age, 74.8 [1.05] years; 7856 women [42.1%]; 10 765 men [57.9%]; 859 Asian [5.2%], 3280 [17.7%] Black, 730 [4.3%] Hispanic, 239 North American Native, and 12 394 managing clinicians. The mean (SD) share of patients with any home dialysis during the first 90 days was 20.6% (7.8%) in the control group and was 0.12 percentage points higher (95% CI, -1.42 to 1.65 percentage points; P = .88) in the ETC group, a statistically nonsignificant difference. None of the secondary outcomes differed significantly between groups.

Conclusions and relevance: The trial results found that in the first year of the US Center for Medicare & Medicaid Innovation-designed ETC model, HRRs assigned to the model did not have statistically significantly different rates in home dialysis compared with control HRRs. This raises questions about the efficacy of the financial incentives provided, although further evaluation is needed, as the size of these incentives will increase in subsequent years.

Trial registration: ClinicalTrials.gov Identifier: NCT05005572.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Drs Ji, Einav, Finkelstein, and Mahoney reported grants from J-PAL North America and the Massachusetts Institute of Technology (MIT) during the conduct of the study. Dr Mahoney reported being currently on leave at the White House National Economic Council from Stanford University and the National Bureau of Economic Research. No other disclosures were reported.

Figures

Figure.
Figure.. CONSORT Diagram of Hospital Referral Region (HRR) Eligibility and Randomization in End-Stage Renal Disease Treatment Choice (ETC)
See this image and copyright information in PMC

Comment in

References

    1. Morgan P, Kirchhoff S. Medicare Advantage (MA) coverage of end stage renal disease (ESRD) and network requirement changes. Accessed August 13, 2022. https://crsreports.congress.gov/product/pdf/R/R46655
    1. Department of Health and Human Services . Advancing American kidney health. Accessed May 23, 2022. https://aspe.hhs.gov/sites/default/files/private/pdf/262046/AdvancingAme...
    1. Fenton SS, Schaubel DE, Desmeules M, et al. . Hemodialysis versus peritoneal dialysis: a comparison of adjusted mortality rates. Am J Kidney Dis. 1997;30(3):334-342. doi:10.1016/S0272-6386(97)90276-6 - DOI - PubMed
    1. Pike E, Hamidi V, Ringerike T, Wisloff T, Klemp M. More use of peritoneal dialysis gives significant savings: a systematic review and health economic decision model. J Clin Med Res. 2017;9(2):104-116. doi:10.14740/jocmr2817w - DOI - PMC - PubMed
    1. Mehrotra R, Chiu YW, Kalantar-Zadeh K, Bargman J, Vonesh E. Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med. 2011;171(2):110-118. doi:10.1001/archinternmed.2010.352 - DOI - PubMed

Publication types

Associated data